Superluminal Medicines secures $60M Series B funding to advance MC4R agonist into Phase I trials for rare genetic obesity.

Peking University researchers develop proteins that activate in nitric oxide-rich inflammatory environments. Breakthrough ...

FDA requests public comment on advancing botanical drug product development pathways. Share your insights on plant-based ...

FDA approves Zanvastro (zilganersen), the first disease-modifying treatment for Alexander disease in pediatric and adult ...

Medicus Pharma licenses Pfizer's discontinued ADC candidate PF-08046031 for $27M upfront and over $1B in potential milestones ...

Milestone Pharmaceuticals' etripamil nasal spray receives China NMPA clearance for PSVT treatment. First regulatory approval ...

Soufflé Therapeutics launches Phase I/II trial of SFL-0821, an antibody-siRNA conjugate targeting DUX4 for ...

Cipla secures exclusive US commercialization rights for QL2107, a pembrolizumab biosimilar, through licensing agreement with ...

Thryv Therapeutics licenses exclusive SGK1 inhibitors from Spanish institutions to advance neurodegeneration treatment.

AbbVie completes $10.9B acquisition of Apogee Therapeutics to expand IL-13 franchise with zumilokibart. Strengthens ...

Gan & Lee Pharmaceuticals licenses bofanglutide European rights to Menarini Group for EUR 726 million. GLP-1 RA obesity ...

France's drug regulator clears SENS-601, an AAV gene therapy for GJB2-related hearing loss. Learn about this breakthrough in ...